Kyverna Therapeutics
KYTX
88 hedge funds and large institutions have $108M invested in Kyverna Therapeutics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 32 increasing their positions, 14 reducing their positions, and 28 closing their positions.
1,960% more call options, than puts
Call options by funds: $206K | Put options by funds: $10K
129% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 14
1.65% more ownership
Funds ownership: 65.22% → 66.88% (+1.7%)
6% less funds holding
Funds holding: 94 → 88 (-6)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
22% less capital invested
Capital invested by funds: $138M → $108M (-$30.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.12M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$935K |
| 4 |
SCM
Superstring Capital Management
New York
|
+$873K |
| 5 |
BlackRock
New York
|
+$729K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.49M |
| 2 |
Millennium Management
New York
|
-$2.43M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.17M |
| 5 |
JP Morgan Chase
New York
|
-$1.06M |
KYTX Hedge Fund Activity: Q4 2024 in Review
88 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q4 2024, worth a combined $108M — down 22% from $138M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of KYTX and 23 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 32 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $2.12M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.49M sold.
- 88 institutional investors held Kyverna Therapeutics (KYTX) as of Q4 2024, down from 94 in Q3 2024.
- Funds reported $108M of Kyverna Therapeutics stock for Q4 2024, down 22% quarter-over-quarter.
- 23 funds opened new Kyverna Therapeutics positions in Q4 2024 and 28 closed out, a net change of -5 holders.
- The largest Kyverna Therapeutics buyer in Q4 2024 was Jacobs Levy Equity Management, an estimated $2.12M added.
- The largest Kyverna Therapeutics seller in Q4 2024 was Deerfield Management, an estimated $4.49M sold.
Based on aggregated 13F filings for Q4 2024.